Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -11.33 is 73% above its 5-year average of -41.73, near the high end of its 5-year range (-69.51–-11.33).
36.69% above its 12-month average of -17.89.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.44.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 27 comparable quarters.
EARNINGS PER SHARE (EPS)
-11.33
EARNINGS PER SHARE (EPS) AVG TTM
-17.89
EARNINGS PER SHARE (EPS) AVG 3Y
-30.77
EARNINGS PER SHARE (EPS) AVG 5Y
-41.73
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+36.69%
CURRENT VS 3Y AVG
+63.18%
CURRENT VS 5Y AVG
+72.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Passage Bio, Inc.
Market Cap
$13.11M
Earnings Per Share (EPS)
-11.33
TTM Avg
-17.89
3Y Avg
-30.77
5Y Avg
-41.73
Market Cap
$13.20M
Earnings Per Share (EPS)
-2.11
TTM Avg
-3.38
3Y Avg
-4.90
5Y Avg
-6.31
Market Cap
$13.30M
Earnings Per Share (EPS)
-1.39
TTM Avg
-1.16
3Y Avg
-1.40
5Y Avg
-1.09
Market Cap
$13.33M
Earnings Per Share (EPS)
-1.87
TTM Avg
-10.75
3Y Avg
-23.11
5Y Avg
-21.98
Market Cap
$12.78M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.74
3Y Avg
-0.71
5Y Avg
-0.50
Market Cap
$12.58M
Earnings Per Share (EPS)
-4.48
TTM Avg
-3.92
3Y Avg
-3.23
5Y Avg
-105.55
Market Cap
$12.48M
Earnings Per Share (EPS)
-0.79
TTM Avg
-0.84
3Y Avg
-2.55
5Y Avg
-4.78
Market Cap
$13.75M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.44M
Earnings Per Share (EPS)
-5.75
TTM Avg
-5.10
3Y Avg
-9.55
5Y Avg
-8.93
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Passage Bio, Inc. (PASG) | $13.11M | -11.33 | -17.89 | -30.77 | -41.73 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | -2.11 | -3.38 | -4.90 | -6.31 |
| Optimi Health Corp. (OPTH)vs › | $13.30M | -1.39 | -1.16 | -1.40 | -1.09 |
| IN8bio, Inc. (INAB)vs › | $13.33M | -1.87 | -10.75 | -23.11 | -21.98 |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | -0.47 | -0.74 | -0.71 | -0.50 |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | -4.48 | -3.92 | -3.23 | -105.55 |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | -0.79 | -0.84 | -2.55 | -4.78 |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | -5.75 | -5.10 | -9.55 | -8.93 |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | -5.41 | -10.52 | -27.78 | -33.88 |
Trailing EPS (TTM)
$-11.33
Forward EPS (Est.)
$-9.78
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -14.35 |
| 2024-12-31 | -21.44 |
| 2023-12-31 | -37.29 |
| 2022-12-31 | -50.00 |
| 2021-12-31 | -69.51 |
| 2020-12-31 | -57.80 |
| 2019-12-31 | -45.60 |
| 2018-12-31 | -10.60 |
